Brian Schwartz

Brian has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries, spanning several therapeutic areas including oncology, hematology, dermatology, neurology, and rare diseases. During the past decade Brian has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. in 2020. Prior to ArQule Inc., Brian was CMO at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma. Brian is a Board Member of Enlivex Therapeutics, Cyclacel and Infinity Pharmaceuticals, an advisor for the California Institute of Regenerative Medicine and acts as an independent consultant for numerous biotech companies. Brian received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada, and practiced medicine prior to his career in the biopharmaceutical industry.